Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXNHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SLXN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.40M
- EPS (TTM)
- -$27.21
- Dividend yield
- None
- 52-week range
- 0.222 – 40.70
- Day range
- 0.2225 – 0.2499
- Volume / Avg
- 1.48M / 9.90M
- Beta
- —
- Shares outstanding
- 14.47M
52-week range
SLXN stock today
Silexion Therapeutics (SLXN) closed at $0.2349 on Oct 8, down 7.37% (-$0.0187), versus the S&P 500's 0.47% decline. Trading was light, with 1.48M shares changing hands, about 15% of the average daily volume. Shares are 99.4% below their 52-week high of $40.70 and 5.8% above the 52-week low of $0.222, near the bottom of the past year's range.
Silexion Therapeutics has posted a net loss over the last twelve months (EPS of -$27.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Silexion Therapeutics
Company profileSilexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ilan Hadar M.B.A.
- Headquarters
- Jerusalem
- Employees
- 13
- Website
- silexion.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$5.00+2028.57%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Silexion Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SXTP60 Degrees Pharmaceuticals Inc. | 0.9725 | -11.59% | $3.42M | vs SLXN |
| HCWBHCW Biologics Inc. | 1.53 | -1.92% | $3.42M | vs SLXN |
| ONCOOnconetix Inc. | 0.6543 | +9.56% | $3.43M | vs SLXN |
| XRTXXORTX Therapeutics Inc. | 1.85 | +6.02% | $3.36M | vs SLXN |
| CMNDClearmind Medicine Inc. | 6.60 | 0.00% | $3.35M | vs SLXN |
| CVKDCadrenal Therapeutics Inc. | 0.9296 | -4.39% | $3.32M | vs SLXN |
| APVOAptevo Therapeutics Inc. | 1.80 | -2.17% | $3.26M | vs SLXN |
| KAPAKairos Pharma Ltd. | 0.9595 | +10.29% | $3.25M | vs SLXN |
Indexes, lists and sector
Appears in lists
Silexion Therapeutics stock FAQ
What is Silexion Therapeutics's stock price today?
SLXN last traded at $0.2349 as of Oct 8, 4:00 PM EDT, down 7.37% on the day. Prices are delayed at least 15 minutes.
Who is Silexion Therapeutics's CEO?
Mr. Ilan Hadar M.B.A. is the chief executive officer of Silexion Therapeutics Corp, which has about 13 employees.
What is the SLXN 52-week high?
The 52-week high for SLXN is $40.70 and the 52-week low is $0.222. The stock is currently 99.4% below its high.